Guideline‑Recommended Management of Uncontrolled Stage 2 Hypertension

Definition and Initial Pharmacologic Strategy

Stage 2 hypertension (≥140 mmHg systolic or ≥90 mmHg diastolic) warrants initiation of two first‑line agents from different classes, preferably as a single‑pill fixed‑dose combination. The American College of Cardiology/American Heart Association (ACC/AHA) 2025 guidelines define this threshold and recommendation. 1

The ACC/AHA 2025 guidelines list thiazide or thiazide‑like diuretics as first‑line agents for hypertension and support adding a low‑dose thiazide when blood pressure remains uncontrolled on an ACE‑inhibitor ± calcium‑channel blocker regimen. 1
Adding a thiazide diuretic to an ACE‑inhibitor + calcium‑channel blocker creates a rational three‑drug regimen that targets complementary pathophysiologic mechanisms (renin‑angiotensin system, vascular smooth‑muscle tone, and sodium‑water balance). This strategy is endorsed by Praxis Medical Insights (2026). 2

In the setting of markedly elevated blood pressure (≈190/90 mmHg), dizziness is unlikely to be caused by medication‑induced hypotension; therefore, clinicians should not reduce antihypertensive therapy because of dizziness. Undertreatment carries a substantially higher risk of stroke, myocardial infarction, heart failure, and death. ACC/AHA 2025 guideline (Class I). 1

Stress‑management interventions (e.g., mindfulness‑based stress reduction, cognitive‑behavioral therapy, yoga, progressive muscle relaxation) receive a Class I recommendation in the ACC/AHA 2025 hypertension guideline. 1
Lifestyle modifications are mandatory adjuncts to drug therapy per the ACC/AHA 2025 guideline and include:
- Adoption of the DASH dietary pattern (high in fruits, vegetables, whole grains, low‑fat dairy). 2
- Sodium restriction to approximately 2 g per day. 2
- Regular moderate‑intensity aerobic exercise (30–60 min on 4–7 days per week). 2
- Limiting alcohol intake to ≤2 standard drinks per day. 2
- Weight loss when body‑mass index exceeds 24.9 kg/m². 2
Stress alone does not explain a blood pressure of 190/90 mmHg; such a level reflects inadequate pharmacologic control rather than transient stress reactivity. 2

Home blood pressure monitoring is strongly recommended (Class I) by the ACC/AHA 2025 hypertension guideline to improve control rates. 1
Validated automated cuffs can be obtained at low cost (≈$20–40) or loaned by health‑system programs; community health centers, fire stations, and pharmacies often provide free BP checks. (Praxis Medical Insights, 2026). 2
The ACC/AHA 2025 guideline advises against reliance on smartwatch or cuff‑less devices due to insufficient accuracy. 1

If blood pressure remains uncontrolled on three or more antihypertensive agents, clinicians should screen for secondary causes such as primary aldosteronism, renal artery stenosis, obstructive sleep apnea, and pheochromocytoma, as recommended by the ACC/AHA 2025 guideline. 1

Do not attribute severe hypertension (≈190/90 mmHg) solely to stress, as this delays necessary medication intensification and increases cardiovascular risk. ACC/AHA 2025 guideline (Class I). 1
Do not withhold medication uptitration because of dizziness when blood pressure is markedly elevated; the risk of major cardiovascular events outweighs potential medication‑related side effects. ACC/AHA 2025 guideline (Class I). 1
Do not rely exclusively on a single emergency‑room blood pressure reading; such measurements may be influenced by acute stress or pain, and a reading of ≈190/90 mmHg warrants prompt outpatient therapy escalation. ACC/AHA 2025 guideline (Class I). 1